drugset / Trial / NCT06079476

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

NCT06079476

Phase 4 Completed 100 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.

Timeline

Start
2023-10-30
Primary completion
2025-10-18
Completion
2025-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Romosozumab Monoclonal antibody Subcutaneous